Bergesio F, Ciuti R, Salvadori M, Galli G A, Monzani G, Bertoni E, Salerno A, Frizzi V
Department of Nephrology and Dialysis, New Hospital of S. Giovanni di Dio, Florence, Italy.
Int J Artif Organs. 1989 Nov;12(11):677-82.
Patients on chronic hemodialysis often present both hyperlipidemia and a high incidence of cardiovascular disease (CVD). Uremic hyperlipidemia has usually been regarded as one of the most important cardiovascular risk factors (CVRF) in these patients. In order to study whether the "uremia-induced" lipid abnormalities are actually associated with evidence of uremic CVD, and consequently may be considered reliable CVRF, 123 patients on chronic dialysis were reviewed for the presence of CVD and, at the same time, examined for their lipoprotein pattern and other clinical and biochemical variables. Lipids and lipoproteins did not prove helpful in our study in identifying patients with CVD. Despite the fact that they had been on dialysis for a shorter time, CVD patients were significantly older and had higher blood pressure than patients without CVD. Our data suggest that the uremia-induced lipid abnormalities are not reliable markers of CVD in dialysis patients, and support the hypothesis that dialysis per se does not accelerate the atherosclerotic process in uremic patients.
接受慢性血液透析的患者常常同时存在高脂血症和心血管疾病(CVD)的高发病率。尿毒症性高脂血症通常被视为这些患者最重要的心血管危险因素(CVRF)之一。为了研究“尿毒症诱导的”脂质异常是否实际上与尿毒症性CVD的证据相关,进而是否可被视为可靠的CVRF,我们对123例慢性透析患者进行了CVD存在情况的回顾,并同时检查了他们的脂蛋白谱以及其他临床和生化变量。在我们的研究中,脂质和脂蛋白在识别CVD患者方面并无帮助。尽管CVD患者接受透析的时间较短,但他们的年龄显著大于无CVD的患者,且血压更高。我们的数据表明,尿毒症诱导的脂质异常并非透析患者CVD的可靠标志物,并支持这样一种假说,即透析本身并不会加速尿毒症患者的动脉粥样硬化进程。